Healthleap Secures $38M to Expand AI Screening for Undiagnosed Hospital Conditions

Healthleap, a startup using artificial intelligence to scan patient records for signs of undiagnosed illnesses, has secured $38 million in a combined seed and Series A funding round. The investment, led by prominent venture capital firms, validates the company's approach to tackling a persistent problem in healthcare: conditions that are often overlooked during a hospital stay, leading to poorer patient outcomes and significant financial losses for health systems. The new capital is earmarked to scale Healthleap's platform, which is already deployed in over 50 hospitals and has demonstrated substantial financial and clinical impact at major U.S. medical centers.

Founded in 2022 by siblings Jemima and Josiah Meyer, Healthleap aims to move hospitals beyond static, manual screening methods that frequently fail to identify at-risk patients. The company plans to use the funds to expand its platform's capabilities from an initial focus on malnutrition to cover more than 40 major health conditions, while also growing its engineering, product, and sales teams to support a broader rollout into hundreds of hospitals.

Strategic Investment Fuels AI Platform Expansion

The $38 million financing consists of an $8 million seed round co-led by Sequoia Capital and First Round Capital, followed by a $30 million Series A round led by Hummingbird Ventures. While Healthleap has not disclosed its valuation, the backing from these high-profile investors signals strong confidence in its technology and business model.

The company's origin stems from a direct clinical need. According to a report from TechRepublic, co-founder Jemima Meyer, a clinical dietitian, recognized that many hospital patients were receiving crucial nutritional interventions far too late. This insight formed the basis for a platform designed to provide an earlier, more accurate signal of patient risk.

Investors have been drawn to the platform's demonstrated ability to deliver tangible results. "We were immediately drawn to Healthleap’s bold vision: imagine if every hospital could use real-time AI to spot overlooked clinical risk, improve patient care, and unlock meaningful reimbursement revenue,” said Josh Kopelman, a co-founder and partner at First Round Capital, in a statement. “That’s exactly what Healthleap is delivering and more, starting with disease-related malnutrition and rapidly expanding across conditions to save lives and hospitals money.”

Healthleap's AI Workflow: From Data to Clinical Action

Healthleap's platform is engineered to replace outdated screening protocols, such as simple admission surveys that can easily miss sedated, confused, or critically ill patients. By integrating directly with a hospital's electronic health record (EHR) system, the AI provides a continuous and comprehensive assessment of every adult inpatient, every day.

The process unfolds in a series of automated steps designed to translate vast amounts of patient data into a clear, actionable signal for care teams:

Comprehensive Data Ingestion: Each morning, the platform ingests the complete medical record for every patient. This includes structured data like laboratory results, vital signs, and medication orders, as well as unstructured information from clinicians' notes. This dynamic approach contrasts sharply with static screening methods that capture only a single moment in time.
AI-Powered Analysis: Healthleap deploys language models to parse the unstructured text in physician and nursing notes, extracting clinical indicators such as recent weight loss, deteriorating appetite, or muscle atrophy. This information is synthesized with structured data to generate a daily risk assessment for specific conditions that are often underdiagnosed.
Seamless Workflow Integration: Crucially, the platform's output is delivered directly into the care team's existing EHR workflow. "Each morning, we write a risk score into the care team’s existing workflow," co-founder Josiah Meyer explained to TechCrunch. This avoids the need for clinicians to learn a new system or log into a separate dashboard, a common barrier to technology adoption in hospitals. The system functions as an early warning, feeding a cleaner signal to downstream clinical documentation and coding teams.

Quantifiable Impact at Leading Health Systems

Healthleap's value proposition is supported by reported results from several prominent academic health systems, where the platform has been shown to generate significant financial returns and improve clinical efficiency. The company utilizes an outcome-based pricing structure, claiming that its system can generate between five and twenty times its annual cost in return on investment for hospitals.

At the Hospital of the University of Pennsylvania, the company's initial malnutrition program produced a reported $23.8 million in annualized financial impact. According to figures published by TechCrunch, this was achieved through a combination of $6.3 million in additional reimbursement and $17.5 million in savings from shorter hospital stays. This demonstrates the platform's dual ability to enhance revenue capture and improve operational efficiency.

In another deployment at Cedars-Sinai, the platform reportedly enabled a 39% increase in malnutrition diagnoses using the same number of staff, contributing to an $11 million annual financial impact. This highlights the system's capacity to improve the productivity of clinical teams by helping them focus their efforts on the patients who need it most.

Future Growth: Expanding Conditions and Hospital Reach

With the new capital, Healthleap is poised to significantly expand the scope and scale of its operations. The company's immediate goal is to broaden its clinical focus beyond malnutrition, which costs the U.S. healthcare system an estimated $58 billion annually, to more than 40 other major health conditions that are frequently missed in the inpatient setting.

This product expansion will be supported by a strategic investment in personnel, with plans to grow its engineering, sales, and customer success teams. Beyond simply adding more conditions, Healthleap also has a long-term vision to extend its monitoring capabilities into outpatient and home care settings, suggesting a strategy to manage patient risk across the entire care continuum.

The company's ability to execute this expansion will be a critical test of its technology and business model. Scaling from a single, well-defined condition like malnutrition to a diverse array of over 40 distinct clinical challenges will require sophisticated model development and validation to maintain the accuracy and clinical utility that has driven its early success.

Evaluating Healthleap's Market Trajectory

Healthleap's substantial funding from top-tier investors, combined with its demonstrated impact at prestigious health systems, positions it for significant expansion in the competitive clinical AI market. The company's platform addresses two of the most pressing issues for hospital administrators: improving the quality of patient care and strengthening financial stability. By integrating seamlessly into existing workflows and delivering a clear return on investment, Healthleap has developed a compelling case for adoption.

The company's success will now depend on its ability to replicate its initial results across a wider range of medical conditions and a larger, more diverse network of healthcare providers. The key metric for evaluating its progress will be Healthleap's expansion into new conditions and additional hospital system partnerships.